Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma / 医学前沿

Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.

The value of enteral immunonutrition in therapeutic hepatectomy for patients with primary liver cancer / 重庆医科大学学报

Objective: The aim of this study was to investigate the immune function and prognosis for patients with primary hepatic cancer who implemented the perioperative enteral immunonutrition support for hepatectomy.Methods: 58 cases of patients with primary hepatic cancer in our hospital in 2003 treated with liver resection were randomly divided into nutritional support fur immune nutrition group and conventional control group.Immune function was detected on admission,1st day and 7th after surgery;5-year follow-up was performed to compare the prognosis of the two groups. Results: Concentration level of CD3+,CD4+,CD8+and CD4+ICD8+in preoperative hepatectomy were the same between the two groups. On the first day after surgery,CD3+,CD4+,CD8+content decreased significantly; there was no difference between the two groups. On the 7th day after surgery,CD3+,CD4+,CD8+content increased;and the intervention group increased more significantly.1,2,3,4,and 5-year survival rates in intervention group and control group were 82.8%,70.2%, 39.6%,22.6%.20.6%and 74.6%,50.1%,25.4%,21.5%,19.5%.The survival rate was higher in the intervention group than the control group at 1-year,2-year and 3-year,while the 4 and 5-yearsurvival rate of the two groups was same,and the intervention group had better overall survival compared with the control group(X~2=3.547,P=0.025).The OR value for enteral immunonutrition support impacting postoperative survival was 0.649 after multivariate analysis adjusted.with 95.0%CI of 0.614-0.686.Conclusion:Enteral immunonutrition support can ameliorate immune suppression in hepatectomy for patients with primary liver cancer during perioperative period,and it also Can improve postoperative survival.